Steroid 5α-reductases and 3α-hydroxysteroid dehydrogenases: Key enzymes in androgen metabolism

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 15, Issue 1, 2001, Pages 79-94

  Jin, Yi ^a   Penning, Trevor M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 dihydrotestosterone; Aldo keto reductase; Intracrine modulation; Isozymes; Prostate disease

Indexed keywords

3ALPHA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANEDIOL; ANDROSTANOLONE; STEROID 5ALPHA REDUCTASE; STEROID HORMONE ANTAGONIST; TESTOSTERONE; 3 ALPHA HYDROXYSTEROID DEHYDROGENASE (B SPECIFIC); 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE;

ANDROGEN METABOLISM; BIOSYNTHESIS; CATABOLISM; DISORDERS OF HORMONE METABOLISM; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; INTRACELLULAR TRANSPORT; PROTEIN DEGRADATION; PROTEIN TARGETING; RECEPTOR UPREGULATION; REVIEW; ANIMAL; METABOLISM;

3-ALPHA-HYDROXYSTEROID DEHYDROGENASE (B-SPECIFIC); 3-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; ANIMALS; HUMANS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0034743536     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2001.0120     Document Type: Article

References (49)

1. Steroid receptor family: Structure and functions
2. Steroid hormone receptors
3. Intracrinology. Autonomy and freedom of peripheral tissues
4. Androgens
5. Relative binding affinity of anabolic-androgenic steroids: Comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin
6. Steroid 5α-reductase: Two genes/two enzymes
7. Molecular endocrinology of hydroxysteroid dehydrogenases
8. The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia: The finasteride study group
9. Endocrine treatment of prostate cancer
10. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
11. TA repeat polymorphism of the 5α-reductase gene and breast cancer
12. Regulation of sexual differentiation in drug and steroid metabolism
13. Androgen-induced regrowth in the castrated rat ventral prostate: Role of 5α-reductase
14. Factors controlling the expression of 5α-reductase in human prostate: A possible new approach for the treatment of prostate cancer
15. Steroid 5α-reductase 2 deficiency
16. 5α-reduced androgens play a key role in murine parturition
17. Analysis of the steroid binding domain of rat steroid 5α-reductase (isozyme-I) the steroid D-ring binding domain of 5α-reductase
18. Identification of the NADP(H) binding sites of rat liver microsomal 5α-reductase (isozyme-I): Purification of a photolabeled peptide corresponding to the adenine binding domain
19. Site-directed mutagenesis studies of the NADPH-binding domain of rat steroid 5α-reductase (isozyme-I): Analysis of aromatic and hydroxylated amino acid residues
20. Structure and function of 3α-hydroxysteroid dehydrogenase
21. A new nomenclature for the aldo-keto reductase superfamily
22. Purification and properties of multiple forms of dihydrodiol dehydrogenase from human liver
23. Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: Oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a] pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione
24. Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: Demonstration of bifunctional 3α/17β-HSD activity and cellular distribution
25. cDNA cloning and expression of the human hepatic bile acid-binding protein. A member of the monomeric reductase gene family
26. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells
27. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: Functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones
28. Expression cloning and characterization of oxidative 17β- and 3α-hydroxysteroid dehydrogenases from rat and human prostate
29. Identification of the oxidative 3α-hydroxysteroid dehydrogenase activity of rat Leydig cells as Type II retinol dehydrogenase
30. Cloning, sequencing, and functional analysis of the 5′-flanking region of the rat 3α-hydroxysteroid/dihydrodiol dehydrogenase gene
31. Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3α-hydroxysteroid dehydrogenases
32. Genomic organization and chromosomal localization of a novel human hepatic dihydrodiol dehydrogenase with high affinity bile acid binding
33. Structure of the human aldose reductase gene
34. Localization of multiple human dihydrodiol dehydrogenase (DDH1 and DDH2) and chlordecone reductase (CHDR) genes in chromosome 10 by the polymerase chain reaction and fluorescence in situ hybridization
35. Structure of a gene coding for human dihydrodiol dehydrogenase/bile acid-binding protein
36. Promoter analysis of a human dihydrodiol dehydrogenase
37. Rat dihydrodiol dehydrogenase: Complexity of gene structure and tissue-specific and sexually dimorphic gene expression
38. Dexamethasone regulation of the rat 3α-hydroxysteroid/dihydrodiol dehydrogenase (3α-HSD/DD) gene
39. Members of the nuclear factor I transcription factor family regulate rat 3α-hydroxysteroid/dihydrodiol dehydrogenase (3α-HSD/DD AKR1C9) gene expression: A member of the aldo-keto reductase superfamily
40. Three-dimensional structure of rat liver 3α-hydroxysteroid/dihydrodiol dehydrogenase: A member of the aldo-keto reductase superfamily
41. +
42. + bound to 3α-hydroxysteroid/dihydrodiol dehydrogenase
43. Mutagenesis of 3α-hydroxysteroid dehydrogenase reveals a 'push-pull' mechanisms for proton transfer in aldo-keto reductases
44. Overexpression and mutagenesis of the cDNA for rat liver 3α-hydroxysteroid/dihydrodiol dehydrogenase. Role of cysteines and tyrosines in catalysis
45. Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase
46. Dihydrotesterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia
47. Role of 5α-reductase inhibitors in the treatment of advanced prostatic carcinoma
48. Inhibitors of steroid 5α-reductase in benign prostatic hyperplasia, male pattern baldness and acne
49. 5α-Reductase inhibitors, chemical and clinical models